Details of the Drug Formulations

General Information of Drug (ID: DMNLHAC)

• Drug Name: Allopregnanolone Drug Info
• Synonyms: 516-54-1; Brexanolone; Allotetrahydroprogesterone; Allopregnan-3alpha-ol-20-one; 3alpha-hydroxy-5alpha-pregnan-20-one; SAGE-547; UNII-S39XZ5QV8Y; 3-alpha,5-alpha-Pregnanolone; 3alpha-OH DHP; 3alpha,5alpha-THP; 5alpha-Pregnan-3alpha-ol-20-one; 3a-Hydroxy-5a-pregnan-20-one; 3a,5a-THP; (3alpha)-Allopregnanolone; 3-alpha,5-alpha-Tetrahydroprogesterone; BRN 3211363; S39XZ5QV8Y; 3alpha-Hydroxy-5alpha-dihydroprogesterone; 3-alpha-Hydroxy-5-alpha-pregnan-20-one; CHEMBL207538; CHEBI:50169; SGE-102

Indication

Disease Entry	ICD 11	Status	REF
Depression	6A70-6A7Z	Approved	[1]
Postpartum depression	6E20.0	Approved	[1]
Status epilepticus seizure	8A66.1Y	Phase 3	[2]
Essential tremor or related tremors	8A04.1	Phase 2	[3]

• Cross-matching ID:
  PubChem CID: 92786
  ChEBI ID: CHEBI:50169
  CAS Number: 516-54-1
  TTD ID: D00VZZ
  INTEDE ID: DR0226
  ACDINA ID: D00891

Full List of Drug Formulations Containing This Drug

Brexanolone 100 mg/20 ml Injection

Company	Formulation ID	FDA Description
Sage Therapeutics	F23092	Betadex Sulfobutyl Ether Sodium; Citric Acid Monohydrate; Sodium Citrate Dihydrate; Water For Injection; Hydrochloric Acid; Sodium Hydroxide

References

• [1] Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
• [2] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [3] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)